CNBC·2026-02-24 20:38Core Viewpoint - Novo Nordisk's next-generation obesity drug, CagriSema, has underperformed compared to Eli Lilly's Zepbound in a phase three trial, raising concerns about its market potential and competitive positioning [2][3]. Group 1: Trial Results and Market Implications - CagriSema demonstrated slightly less weight loss than Zepbound after 84 weeks, leading analysts to question why patients would choose CagriSema over the more effective Zepbound [3]. - Analysts from BMO and JPMorgan highlighted that the trial results will hinder CagriSema's ability to gain market share from Lilly, reinforcing Zepbound's status as a market leader [4]. - Novo Nordisk's CEO expressed confidence in CagriSema's efficacy, stating it offers clinically meaningful weight loss effects superior to existing GLP-1 targeting drugs [5][6]. Group 2: Future Trials and Development Plans - Novo is optimistic about upcoming trials, including the REDEFINE 11 trial, which will compare CagriSema to a placebo in 600 adults, with initial results expected in the first half of 2027 [7]. - The company plans to initiate a phase three trial for a higher dose of CagriSema in the second half of 2026, hoping to replicate the greater efficacy seen with higher doses of Wegovy [8]. - Novo's existing drug Wegovy achieves around 15% to 16% weight loss at standard doses, with higher doses approaching 21% [9]. Group 3: Competitive Landscape and Strategic Moves - Novo Nordisk faces significant competition from Lilly, which is set to launch a next-generation obesity drug that has shown over 28% weight loss in clinical trials [9]. - The company previously invested $2 billion in a Chinese drugmaker's experimental medicine that operates similarly to Lilly's upcoming treatment, indicating a strategic move to enhance its pipeline [10]. - Novo's CEO has indicated plans for active deal-making to complement its pipeline, suggesting a focus on mergers and acquisitions as a potential strategy to bolster its competitive position [10].